We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
WDR18
SECTIONS
  • TISSUE
  • BRAIN
  • SINGLE CELL TYPE
  • TISSUE CELL TYPE
  • PATHOLOGY
  • DISEASE
  • IMMUNE CELL
  • BLOOD PROTEIN
  • SUBCELLULAR
  • CELL LINE
  • STRUCTURE
  • METABOLIC
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
  • SARS-COV-2
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Patient ID
Tissue
Category
Cluster
Reliability
Brain region
Category
Brain region
Category
Brain region
Category
Reliability
Cell type
Category
Cluster
Tissue
Cell type
Enrichment
Cancer
Prognosis
Cancer
Category
Cell type
Category
Cell lineage
Category
Cluster
Annotation
Disease
Location
Searches
Location
Cell line
Type
Phase
Reliability
Cancer type
Category
Cluster
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Protein structure
In atlas
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • TISSUE CELL

  • PATHOLOGY

  • DISEASE

  • IMMUNE

  • BLOOD

  • SUBCELL

  • CELL LINE

  • STRUCTURE

  • METABOLIC

  • WDR18
PROTEIN SUMMARY SECTION OVERVIEW RNA DATA ANTIBODY DATA
Antibody HPA050193 Antibody HPA050200
ANTIBODY INFORMATION
Provider Atlas Antibodies
Sigma-Aldrich
Atlas Antibodies
Sigma-Aldrich
Product name HPA050193 HPA050200
Host species Rabbit Rabbit
Clonalityi

The antibodies are designated mAB for monoclonal and pAb for polyclonal.

pAb pAb
Concentration 0.0454 mg/ml 0.0431 mg/ml
Purity Affinity purified using the PrEST-antigen as affinity ligand Affinity purified using the PrEST-antigen as affinity ligand
Released in versioni

The release of the Human Protein Atlas in which the antibody was first published.

11.0 11.0
Proper citation Atlas Antibodies Cat#HPA050193, RRID:AB_2681047 Atlas Antibodies Cat#HPA050200, RRID:AB_2681049
Validation summaryi

All assays through which the antibody has been validated. Assays&annotation provide a detailed description of the different assays. The pie-charts indicate degree of validation.

ICC 
IHC 
WB 
PA 
N/A
ICC
IHC 
WB 
PA 
IMMUNOCYTOCHEMISTRYi

Immunocytochemistry is used to validate the antibody staining and for assessing and validating the protein expression pattern in selected human cell lines.

Read more
Validationi

Results of validation by standard or enhanced validation.

Standard validation is based on concordance with available experimental gene/protein characterization data in the UniProtKB/Swiss-Prot database. Standard validation results in scores Supported, Approved or Uncertain.

Enhanced validation is performed using either siRNA knockdown, tagged GFP cell lines or independent antibodies. For the siRNA validation the decrease in antibody-based staining intensity upon target protein downregulation is evaluated. For the GFP validation the signal overlap between the antibody staining and the GFP-tagged protein is evaluated. For the independent antibodies validation the evaluation is based on comparison of the staining of two (or more) independent antibodies directed towards independent epitopes on the protein.

For all cases except the siRNA validation, an image representative of the antibody staining pattern is shown. For the siRNA validation, a box plot of the results is shown.

Read more
Supportedi

Immunocytochemistry is used for validating antibody reliability by assessing staining pattern in cell lines. Validation scores include Enhanced, Supported, Approved and Uncertain.

Read more


The subcellular location is supported by literature.
Immunofluorescent staining of human cell line MCF-7 shows localization to nucleoplasm.
N/A
Antibody dilution
Human assay: HEK293 fixed with PFA, dilution: 1:23
Human assay: MCF-7 fixed with PFA, dilution: 1:23
IMMUNOHISTOCHEMISTRYi

Immunohistochemistry is used for validating antibody reliability by assessing staining pattern in 44 normal tissues. Validation scores include Enhanced, Supported, Approved and Uncertain.

Read more
Validationi

Results of validation by standard or enhanced validation based on assessment of antibody performance in 44 normal tissues.

Standard validation results in scores Supported, Approved or Uncertain. An image representative of the antibody staining pattern is shown.

Enhanced validation results in the score Enhanced and includes two methods: Orthogonal validation and Independent antibody validation. For orthogonal validation, representative images of high and low expression are shown. For independent antibody validation, four images of each independent antibody are displayed.

Read more
Approvedi

Immunohistochemistry is used for validating antibody reliability by assessing staining pattern in 44 normal tissues. Validation scores include Enhanced, Supported, Approved and Uncertain.

Read more

Immunohistochemical staining of human caudate shows strong nuclear positivity in neuronal cells.
Caudate
Approvedi

Immunohistochemistry is used for validating antibody reliability by assessing staining pattern in 44 normal tissues. Validation scores include Enhanced, Supported, Approved and Uncertain.

Read more

Immunohistochemical staining of human duodenum shows strong cytoplasmic and membranous positivity in glandular cells.
Duodenum
Retrievali

Antigen retrieval is a method used to restore/retrieve the epitope (antibody bidning region) of the target protein, cross-linked, and thus masked, during tissue preserving fixative treatment of the tissues.

Read more
HIER pH6 HIER pH6
Antibody dilution 1:75 1:30
Literature conformityi

Conformance of the expression pattern with available gene/protein characterization data in scientific literature and data from bioinformatic predictions.

UniProt is used as the main source of gene/protein characterization data and when relevant, available publications and other sources of information are researched in depth. Extensive or sufficient gene/protein data requires that there is evidence of existence on a protein level and that a substantial quantity of published experimental data is available from literature and public databases. Limited protein/gene characterization data does not require evidence of existence on a protein level and refers to genes for which only bioinformatic predictions and scarce published experimental data is available.

No avaliable gene/protein characterization data. No avaliable gene/protein characterization data.
RNA consistencyi

Consistency between immunohistochemistry data and consensus RNA levels is divided into five different categories: i) High consistency, ii) Medium consistency, iii) Low consistency, iv) Very low consistency, and v) Cannot be evaluated.

Medium consistency between antibody staining and RNA expression data. Medium consistency between antibody staining and RNA expression data.
WESTERN BLOTi

A Western blot analysis is performed on a panel of human tissues and cell lines to evaluate antibody specificity. For antibodies with unreliable result a revalidation using an over-expression lysate is performed.

Read more
Validationi

Western Blot is used for quality control of the polyclonal antibodies generated in the project. After purification, the antibodies are used to detect bands in a setup of lysate and different tissues. The result is then scored Enhanced, Supported, Approved, or Uncertain.

Enhanced validation includes five different methods: Genetic validation, Recombinant expression validation, Independent antibody validation, Orthogonal validation and Capture MS validation.

Read more
Enhanced - Independent antibodiesi

This method is based on comparing the staining pattern using two independent antibodies with no overlapping epitopes. The staining of the two antibodies is compared by Western blot through analyses of samples from at least two cell lysates preferably expressing the target protein at different levels. The results show similar Western Blot patterns achieved with independent antibodies.


Antibody band pattern is confirmed by antibody HPA050200.
Analysis performed using a standard panel of samples.
250
130
95
72
55
36
28
17
10
Enhanced - Orthogonali

This method is based on manual evaluation by comparing the antibody band intensity against the corresponding protein levels quantified by mass spectrometry (MS) or expression determined by RNA-seq. Antibodies are considered enhanced where the staining intensity and protein expression levels show the same expression pattern. A standard panel of two cell lines (RT4 and U-251) are used and the target protein must express the target at different levels.


Antibody band intensities is confirmed by MS TMT data.
250
130
95
72
55
36
28
17
10
Enhanced - Capture MSi

This method is based on comparison between the molecular weight of the stained band visualized by the antibody against the protein size obtained by a capture MS method in which multiple gel slices are cut out from the electrophoretic separation of cell lysates of RT4 and U-251 and analysed separately by proteomics. The band detected by the antibody should be equivalent to the same of the intended target protein and its peptide(s).


Antibody band pattern is confirmed by capture-MS.
250
130
95
72
55
36
28
17
10

Enhanced - Independent antibodiesi

This method is based on comparing the staining pattern using two independent antibodies with no overlapping epitopes. The staining of the two antibodies is compared by Western blot through analyses of samples from at least two cell lysates preferably expressing the target protein at different levels. The results show similar Western Blot patterns achieved with independent antibodies.


Antibody band pattern is confirmed by antibody HPA050193.
Analysis performed using a standard panel of samples.
250
130
95
72
55
36
28
17
10
Enhanced - Capture MSi

This method is based on comparison between the molecular weight of the stained band visualized by the antibody against the protein size obtained by a capture MS method in which multiple gel slices are cut out from the electrophoretic separation of cell lysates of RT4 and U-251 and analysed separately by proteomics. The band detected by the antibody should be equivalent to the same of the intended target protein and its peptide(s).


Antibody band pattern is confirmed by capture-MS.
250
130
95
72
55
36
28
17
10

Antibody dilution Independent: 1:110
Orthogonal MS: 1:110
Capture MS: 1:110
Independent: 1:110
Capture MS: 1:110
PROTEIN ARRAY
Validationi

A protein array containing 384 different antigens including the antibody target is used to analyse antibody specificity. Depending on the array interaction profile the antibody is scored as Supported, Approved, or Uncertain.

Read more
Approved

Pass with quality comment low specificity (binding to 1-2 antigens >15% and <40%).
Antibody specificity analysis with protein arrays. Predicted and matching interactions are shown in green.
Supported

Pass with single peak corresponding to interaction only with its own antigen.
Antibody specificity analysis with protein arrays. Predicted and matching interactions are shown in green.
Antibody dilution 1:900 1:850
ANTIGEN INFORMATION
Antigen Recombinant protein fragment Recombinant protein fragment
Length (aa) 89 80
Antigen sequence LPHFNKHLLGAEHGDEPRHGGLTLRLGLHQQGSEPSYLDRTEQLQAVLCS TMEKSVLGGQDQLRVRVTELEDEVRNLRKINRDLFDFST AEHHMFCGGSEGSIFQVDLFTWPGQRERSFHPEQDAGKVFKGHRNQVTCL SVSTDGSVLLSGSHDETVRLWDVQSKQCIR
Matching transcripts WDR18-201 - ENSP00000251289 [100%]
WDR18-202 - ENSP00000476117 [100%]
WDR18-211 - ENSP00000475744 [100%]
WDR18-202 - ENSP00000476117 [100%]
WDR18-204 - ENSP00000464855 [100%]
WDR18-211 - ENSP00000475744 [100%]
WDR18-201 - ENSP00000251289 [98%]
Matching mouse transcripts ENSMUSP00000041049 [75%]
ENSMUSP00000116189 [25%]
ENSMUSP00000123880 [25%]
ENSMUSP00000041049 [85%]
ENSMUSP00000146707 [32%]
ENSMUSP00000147061 [32%]
ANTIGEN VIEWi

The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.

At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.

Below the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).

The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).

If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.

Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
WDR18-201
WDR18-202
WDR18-204
WDR18-211

Contact

  • NEWS ARTICLES
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.